RCS - Poolbeg Pharma PLC - POLB 001 LPS Trial Data to be Presented at IUIS

Poolbeg PharmaAnnouncement

16/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231116:nRSP6177Ta&default-theme=true

RNS Number : 6177T  Poolbeg Pharma PLC  16 November 2023

Poolbeg Pharma plc

 

POLB 001 LPS Challenge Trial Data to be Presented at IUIS

 

POLB 001 - a potential blockbuster immunomodulator

 

16 November 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company
focussed on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces that an abstract
highlighting the potential of POLB 001 as a groundbreaking therapy has been
accepted for presentation at the 18 (https://iuis2023.org/) (th
(https://iuis2023.org/) ) International Congress of Immunology
(https://iuis2023.org/) ('IUIS'), to be held 27 November - 2 December 2023 in
Cape Town, South Africa.

IUIS is the world's leading conference in the field of immunology and attracts
immunologists from universities, healthcare providers, independent research
organisations and industry leaders. It serves as a premier platform for the
exchange of the latest cutting-edge discoveries and advancements in
immunological research.

The poster presentation will discuss POLB 001's positive LPS human challenge
trial results. POLB 001 is a potential treatment of severe influenza and
Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. CRS is
a severe inflammatory response, which may be encountered as a side effect of
some therapies, manifesting a range of symptoms that can rapidly progress to a
severe life-threatening reaction. An effective therapy for CRS could unlock
the benefits of cancer immunotherapies, benefiting patients and healthcare
systems alike.

Title: Inhibition of local and systemic inflammatory responses by POLB 001, a
novel p38 MAPK inhibitor, following in vivo LPS administration in healthy
volunteers

Session Date: 1 December 2023

Presentation Time: 12pm - 1pm SAST

Location: Hall 2

Presenter: Digna de Bruin, The Centre for Human Drug Research

 

If you would like to meet with Poolbeg Pharma, get in touch
at partnering@poolbegpharma.com (mailto:partnering@poolbegpharma.com)

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "The
acceptance of this abstract at the upcoming IUIS conference underscores the
potential of POLB 001 as a groundbreaking therapy. Severe influenza and
Cytokine Release Syndrome associated with cancer immunotherapies are
significant problems and an effective drug that can address these issues would
have a significant impact on global health."

 

- Ends -

 

Enquiries

 Poolbeg Pharma Plc                                                    +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)      +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                  +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                               +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                      +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma plc is focussed on the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need. Its
model focusses upon developing its exciting clinical assets and
commercialising approved and marketed drugs to fund the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team and Board have been augmented with
strong commercialisation expertise following the appointment of three former
members of the Amryt Pharma plc leadership team, with the intention of
repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets across cancer
immunotherapies, infectious disease, and oral GLP-1 agonists for obesity and
other metabolic conditions. It uses a cost-effective development philosophy to
generate high quality human data to support partnering and further
development. Its AI-led infectious disease programmes analyse unique data from
human challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial appeal.

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/) @PoolbegPharma.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKELFFXFLZFBE